Evidence map›Paper›PMID 36930513›Full record

ArticleEuropean review for medical and pharmacological sciences2023

COVID-19: booster(s) vs. hospitalization and Intensive Care Unit admission.

O Baydar Toprak, T Akpolat, O Uzun, P Pınar Deniz, N Kokturk, A Varol, E Guzel, M Ercelik, O Gultekin, R Guner and 49 more

Abstract readComment
PubMed Publisher
In one paragraph

Article in European review for medical and pharmacological sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

59 authors at 1 institution in 1 country.

O Baydar ToprakDepartment of Chest Diseases, Faculty of Medicine, Cukurova University, Adana, Turkey. oyabaydarr@yahoo.com.tr.
T Akpolat
O Uzun
P Pınar Deniz
N Kokturk
A Varol
E Guzel
M Ercelik
O Gultekin
R Guner
S Turan
Ş Gökbulut Bektaş
N Coskun
N Bakan
M Nuri Yakar
O Eren Kutsoylu
B Ergan
S Argun Barış
I Başyiğit
H Boyacı
F Çetinkaya
H Çolak
N Aykac
B Baran Ketencioğlu
Z Türe Yüce
S Akkaya Isık
E Serap Yılmaz
S Karaoğlanoğlu
S Berik Safci
G Ozkan
N Kose
D Kizilirmak
Y Havlucu
S Nural
F Kerget
Ö Sunal
A Yuksel
Z Bestepe Dursun
F Deveci
M Kuluozturk
O Ataoglu
M Dursun
S Keskin
M Emin Sezgin
E N Aktepe Sezgin
F Eser
L Akyildiz
M Selim Almaz
B Kayaaslan
I Hasanoğlu
M Bayrak
A Gümüş
G Sağcan
C Cuhadaroglu
H Kucuk
T Onyilmaz
B Mete
O Kilinc
B Oya Itil
Cukurova University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAs the pandemic continues, different vaccine protocols have been implemented to maintain the protection of vaccines and to provide protection against new variants. The aim of this study was to assess hospitalized patients' vaccination status and document the efficacy of boosters. PATIENTS AND

methodsThe patients that were hospitalized due to COVID-19 were enrolled from 28 hospitals in Turkey for five months from September 2021. 5,331 confirmed COVID-19 patients from collaborating centers were randomly enrolled to understand/estimate the distribution of vaccination status in hospitalized patients and to compare the efficacy of vaccination/booster protocols.

results2,779 men and 2,552 women of which 2,408 (45.2%) were admitted to Intensive Care Units participated in this study. It was found that the highest risk reduction for all age groups was found in groups that received 4 doses. Four doses of vaccination for every 3.7 people under 50 years of age, for every 5.7 people in the 50-64 age group, and for every 4.3 people over 65 years of age will prevent 1 patient from being admitted to intensive care. Regardless of the type of vaccine, it was found that the risk of ICU hospitalization decreased in those who were vaccinated compared to those who were not vaccinated. Regardless of the type of vaccine, the ICU risk was found to decrease 1.25-fold in those who received 1 or 2 doses of vaccine, 1.18-fold in those who received 3 doses, and 3.26-fold in those who received 4 doses.

conclusionsThe results suggested that the addition of a fourth dose is more effective in preventing intensive unit care even in disadvantaged groups.

Indexed as

COVID-19AgedCritical CareFemaleHospitalizationHospitalsHumansIntensive Care UnitsMale

Identifiers

PMID36930513
OpenAlexW4327684305

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.